Evidence map›Paper›PMID 42292848›Full record

ReviewFrontiers in pharmacology2026

Atractylenolide III for central nervous system disorders: a review of multi-target mechanisms and therapeutic potential.

Han Li, Ning-Xi Zeng, Lei Ge, Rui-Liang Ye, Yi-Yang Zhuang, Xiao-Na Huang, Qi Liang, Jian V Zhang, Peng Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Han Li *Shenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Ning-Xi Zeng *Medical Research Center, Dalang Hospital of Dongguan, Dongguan, China.
Lei Ge *Shenzhen Key Laboratory of Metabolic Health, Shenzhen Metabolism and Reproductive Targeted Delivery Proof-of-Concept Center, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Rui-Liang YeMedical Research Center, Dalang Hospital of Dongguan, Dongguan, China.
Yi-Yang ZhuangShenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Xiao-Na HuangMedical Research Center, Dalang Hospital of Dongguan, Dongguan, China.
Qi LiangShenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.
Jian V ZhangShenzhen Key Laboratory of Metabolic Health, Shenzhen Metabolism and Reproductive Targeted Delivery Proof-of-Concept Center, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Peng ZhouShenzhen Bao'an Chinese Medicine Hospital, The Seventh Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system disorders (CNSDs) are a leading cause of global mortality and disability, yet treatment options remain limited. Natural compounds derived from traditional Chinese herbs constitute a vital resource for discovering novel neuroprotective agents. Atractylenolide III (ATL-III), a sesquiterpene lactone isolated from the spleen-fortifying herb

Indexed as

Atractylodes macrocephala Koidz.central nervous system disordersnatural medicinal metabolitesneuroprotectionreviewspleen-fortifying

Identifiers

PMID42292848
PMCPMC13259859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.